Pharmaceutical companies are expected to report a mixed start to FY27, with strong domestic business trends in India likely to provide the main support to June-quarter revenue. Recent acquisitions are also seen adding to the top line, helping offset softer momentum in overseas markets.
The US business, however, is expected to remain subdued. Pressure on prices, a weaker contribution from earlier high-value opportunities such as Revlimid-related sales, and a limited boost from new generic launches could restrict growth in that market during the quarter.
Profitability is likely to stay under strain even if revenue holds up. Higher input costs, continued spending on research and development, and elevated selling and administrative expenses are expected to weigh on margins. Freight and other operating costs may also keep earnings improvement limited.
Overall, the Q1FY27 pharma preview points to domestic strength cushioning global weakness rather than broad-based expansion. India-focused demand and acquisition-led additions may help companies deliver steady revenue growth, but margin recovery could remain slow as US pricing pressure and cost burdens persist.
